Drug Profile
Research programme: anti-IL-13 monoclonal antibodies - Amgen
Alternative Names: ABX 100122Latest Information Update: 30 Mar 2010
Price :
$50
*
At a glance
- Originator Amgen
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 11 Sep 2008 Preclinical development is ongoing in the US
- 03 Apr 2006 Preclinical trials in Asthma in USA (unspecified route)